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Introduction
The ethics of biobanking is one of the most controversial issues in current bioethics
and public health debates. For some, biobanks offer the possibility of unprecedented
advances which will revolutionise research and improve the health of future
generations. For others they are worrying repositories of personal information and
tissue which will be used without sufficient respect for those from whom they came.
Wherever one stands on this spectrum, from an ethics perspective biobanks are
revolutionary. Traditional ethical safeguards of informed consent and confidenti-
ality, for example, simply don’t work for the governance of biobanks and as a result
new ethical structures are required. Thus it is not too great a claim to say that
biobanks require a rethinking of our ethical assumptions and frameworks which we
have applied generally to other issues in ethics. This special issue is dedicated to
addressing these issues from the different perspectives of law, philosophy, medical
ethics and sociology. This paper begins with a broad introduction to the ‘ethics of
biobanking’ which maps the key challenges and controversies of biobanking ethics;
it considers; informed consent (its problems in biobanking and possibilities of
participants’ withdrawal), broad consent, the problems of confidentiality, owner-
ship, property and comercialisation issues, feedback to participants and the ethics of
re-contact.
The papers in this special issue were all presented at the eighth international workshop of the Tiss.EU
Project on the theme ‘Biobanking: Ethics, Governance and Regulation’, at the University of
Birmingham, UK, in June 2010.
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Birmingham, UK
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The Inappropriateness of Informed Consent for Biobanking
In recent decades the appropriateness of informed consent as the ‘gold standard’ to
ensure ethical treatment has been questioned both in therapeutic practice and
medical research [11, 17]. This is particularly the case when genetic information is
at stake and in large-scale population studies—thus whether and what consent is
appropriate in biobanking has been at the fore of this debate [4].
Informed consent has been the gold standard of informed consent since its
introduction in the Nuremberg Code which requires that the research subject should
know ‘‘the nature, duration, and purpose of the experiment; the method and means
by which it is to be conducted; all inconveniences and hazards reasonable to be
expected; and the effects upon his health or person which may possibly come from
his participation in the experiment’’ [16]. These requirements were supplemented
and clarified in the many versions of the Declaration of Helsinki. The latest of these,
2008, adds that research subjects should also know the sources of funding, possible
conflicts of interest, the intended benefits, any other relevant aspects and should
have a right to withdraw.
Attaining these standards of informed consent is problematic for a number of
reasons in biobanking. First, and an issue which applies to all genetic material and
information, informed consent concerns only the individual and does not take
account of other connected individuals; second, biobanking is future-orientated,
thus consent cannot be ‘informed’ at the time it is attained as the nature of the future
research is not yet known; third, biobanks are not a research project, but rather a
resource for many many research projects, thus making consent for each individual
research project impractical to the point of impossibility; and fourth, it is not clear
that the ‘right to withdraw’ can be fully respected in biobanking.
Informed Consent Ignores the Rights and Interests of Connected Individuals
A first reason for the inappropriate nature of informed consent as the ethical tool to
ensure ethical practice in biobanking applies to all research using genetic material
and information; namely, that informed consent does not take into consideration the
risks and benefits of current or future research posed to third parties. Unlike other
medical information, genetic information provides information about others in
addition to the individual from whom samples are taken. For instance, genetic tests
on one family member reveal information about the genetic status of other family
members. For example, if an individual tests positive for a genetic condition, such
as Huntington’s disease, or as a carrier of the BRCA1 or BRCA2 (indicators for
breast cancer) this information has relevance for family members (consanguineous
relations may wish to be tested themselves, and sexual partners may desire the
information when making reproductive decisions) [21].
Accordingly, who has access to genetic information and material is not only of
concern to the individual from whom samples are taken as, ‘‘disclosure of genetic
information by individual DNA donors also exposes information about others with
similar genetic profiles’’ ([15], p. 376). The ‘‘key feature about genetic information
is that it is typically information about a family, or even…about a larger community
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not just about an individual patient’’ ([3], p. 34). This is no less true in biobanking
than in other areas of genetic research for, as Rothstein states, the risks of biobank
research, ‘‘go beyond the individual human subjects to population groups with
which the subject is associated as well as the general public’’ ([18], p. 90). Such
risks include the discovery of information that will affect the health of the subject’s
genetic relations and the possible discriminatory use of the information discovered
against certain cultural, geographical and age-related groups [1]. Thus ethical
mechanisms are required which consider the rights and interests of those connected
to the individual from which samples are taken, whether the family group or the
public in general, as well as from the individual [20, 22, 23]. Informed consent
clearly cannot take third party rights and interests into account and thus is not fit for
purpose when it comes to the ethics and governance of biobanks.
The Future-Orientated Nature of Biobanks Precludes the Possibility of Being
‘Fully Informed’
The second reason why consent for biobanking cannot be called ‘informed’ is quite
simply because at the point of consent the information necessary to make consent
‘fully informed’ is not available. Thus the ethical worry is that if consent is to
something as yet unknown, how can it be ‘informed’ so as to respect individual
autonomy [12]? At the time of consent it is likely that there is little knowledge about
what specific research will be done using the research subject’s data. Thus, it is
impossible for the research subject to be informed about the purpose, methodology,
risks, funding sources and all the other requirements of informed consent. The
Declaration of Helsinki, and other models of informed consent, assume that consent
takes place at the beginning of a specific research project and the aims, benefits and
risks are fully known. This is simply not the case in biobanking, at best only general
areas of research are known. Sometimes these areas will be more focused, for
instance, a biobank set-up using donations from a patient community to research a
particular disease is likely to be able to anticipate future research projects with some
accuracy, whereas a biobank like UK biobank, which is set-up to ‘‘build a major
resource that can support a diverse range of research intended to improve the
prevention, diagnosis, and treatment of illness and the promotion of health
throughout society’’ ([19], p. 3), could not expect to predict future research with any
degree of certainty. In such cases if there is not full information then there can never
be fully informed consent. Accordingly, ‘‘because it is impossible for the donor to
make an informed choice about the risks and benefits of unspecified future research
protocols, such permission should never be called informed consent’’ ([25],
p. 1180). Thus, the future-orientated nature of biobank research makes it is
impossible for consent in biobanking ever to be informed consent.
Biobanks are Not a Research Resource Not a Research Project
The third problem is that biobanks are not a research project but rather a ‘resource
for research’ or ‘a research library’. Therefore, one solution to the problems of
attaining consent for future projects is to ask for informed consent not for
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participating in the biobank in general, but for the specific research projects. Thus
rather than seek consent for biobank participation, consent is sought at the
beginning of every specific research project which uses the biobank.
However, while this would meet the requirements of the Declaration of Helsinki
to seek consent for each individual research project impractical to the point of
impossibility, the sheer numbers make this unrealistic ([22], 85). Such a requirement
would demand returning to the donors for every new study—and potentially for
every subsequent study which drew on previous data. To do this would not only be
administratively cumbersome but more importantly overly burdensome on the
donors to the point of impossibility. Especially for biobanks which are large-scale
and intended to build and expand over a significant amount of time, such a model of
seeking consent at the beginning of every individual research project is just not
possible. Accordingly biobanks have largely rejected informed consent and moved
to other models of consent, such as broad and blanket consent, often supplemented
with additional ethics and governance mechanisms.
Problems of Meeting the ‘Right to Withdraw’ Criteria
The final issue which makes informed consent problematic in biobanking is the
requirement of the right to withdraw. The Declaration of Helsinki states that the
research subject ‘‘must be informed of the right to refuse to participate at any time
without reprisal’’ [6]. Depending on how participation is interpreted it is not clear
that this is possible in biobanking projects, particularly those which are largescale.
For instance, UK Biobank grants participants the ‘right to withdraw’: ‘‘at any time
and without having to explain why and without penalty’’ ([19], p. 6). However, there
are different possible understandings and levels of withdrawal. For instance UK
biobank offers three withdrawal options: ‘no further contact’, ‘no further access’
and ‘no further use’. However even the most extreme formal withdrawal (‘no further
use’) is qualified: ‘‘UK Biobank would destroy their samples (although it may not be
possible to trace and destroy all distributed anonymised sample remnants) and
would only hold their information for archival audit purposes’’ ([19], p. 9). In
addition, although this most complete withdrawal would prevent information being
used in further analyses ‘‘the participant’s signed consent and withdrawal would be
kept as a record of their wishes’’ and it may of course ‘‘not be possible to remove
their data from analyses that had already been done’’ ([19], p. 9). It is also not
possible to stop data being used in subsequent studies which build on the results of
previous research done based on biobank samples and information. Given the nature
of biobanks, what is possible is limited. However, participants may not regard ‘no
further use’ as full withdrawal; they might imagine full withdrawal would allow
them to remove all records of their involvement. Thus, while the greatest possible
withdrawal options are available it is questionable that biobanking meets the
withdrawal requirements of informed consent as set out in the Declaration of
Helsinki.
Taken together these arguments show why biobanks, particularly large-scale and
long-term biobanks, cannot meet the standards of informed consent as set out in the
Declaration of Helsinki. In addition, especially given the ethical concerns about the
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effectiveness of informed consent for protecting all persons (including third parties),
rejecting informed consent and seeking other ethical frameworks has become a
key—indeed probably the key—ethical issue of biobanking.
Broad Consent
There are a number of possible ethical frameworks which could be adopted in
preference to informed consent. The one most discussed in the literature is broad
consent. Some ethicists do argue that broad or blanket consent alone is a solution to
the problems of informed consent in biobanking, but most do not see this as an
ethical solution on its own as it offers so little protection and few guarantees. In
effect broad consent can be regarded as permission to do anything the recipient
biobank sees fit with genetic material. Whilst it has been suggested that broad
consent ‘can be seen as a means of maximising autonomy’ ([13], p. 196) in the
biobanking context, it could be taken to be its opposite: a wholesale abrogation of
individual autonomy, particularly with regard to knowledge future use of their
material. The worry here is that in giving broad consent, the donor is being informed
of little more than the fact that they have relinquished the access to knowledge about
its future usage. Actual models of broad consent have sought to assuage this
concern; for example the UK Human Tissue Act (2004) maintains the right of the
donor to withdraw their sample at any time, and recommends that they be updated
with any significant change of the purpose to which material may be put, for
example ‘if their samples will or could be used for research involving the
commercial sector’. (2004 para 80) However, given the unknown nature of future
biobank research this alone is rarely thought satisfactory. In addition to this
weakness broad consent, like informed consent, is given by the individual and thus
similarly fails to take into account the rights and interests of third parties. That is,
broad consent, like informed consent, is sought only from the individual from whom
samples are taken and not from those connected to them. Thus what has been
generally suggested is that broad consent is supplemented by other ethics and
governance mechanisms which ensure that ethics is ongoing over time and that the
rights and interests of wider groups, beyond just the participants, are respected [2,
12, 24].
UK Biobank is an example of such a model. Broad consent is used and is
supplemented by other ethics and governance mechanisms which are ongoing for
the lifetime of the project. Thus there are safeguards for both the participant (and
over time) and for those who do not participate but who have a wider interest in the
biobank: The participant is protected by both the broad consent which requires that
UK Biobank must conform with the terms of the original consent and by the
additional ethics and governance mechanisms which ensure that this continues over
time; and connected persons and third parties are protected by the additional ethics
and governance mechanisms which ensure that research happens in the public
interest. In the words of the ethics and governance framework ‘‘UK Biobank will
serve as the steward of the resource, maintaining and building it for the public good
in accordance with its purpose’’ ([19], p. 12).
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Thus, UK Biobank’s participants give broad consent that their samples can be
used in ways which fit the stated purpose of UK Biobank; that is, to ‘‘build a major
resource that can support a diverse range of research intended to improve the
prevention, diagnosis, and treatment of illness and the promotion of health
throughout society’’ ([19], p. 3). When asked to consent participants are asked on
the basis that participation is ‘‘an opportunity to contribute to a resource that may, in
the long-term, help enhance other people’s health’’ ([19], p. 5). While this is a broad
statement of its aims, it does not permit any research at all to be carried out on the
participants samples (the worry that broad consent is overly permissive). Research
must fall within UK Biobank’s stated aim—that ‘‘the resource is being used in the
public interest’’ ([19], p. 13) scientific interest alone is not enough—and ongoing
ethics and governance mechanisms are in place to ensure that this is the case.
Given the reliance on additional ethics and governance mechanisms, much
depends upon the success of these and on how effective they are in holding UK
Biobank to its promise to ensure that research is in the public interest. Determining
the public interest in detail is potentially problematic, however, broad principles are
not difficult to determine. For instance, research which posed a public health risk
would be unacceptable—whatever the expected scientific benefit—as perhaps
would be research leading to developments which the donor group would not have
access to (for instance, due to a high cost). Thus the public interest must be a
determining criterion when it comes to allowing access to the resource. In UK
biobank this is required in the Ethics and Governance Framework which sets out the
aims of UK Biobank, with which UK Biobank is bound to comply, and
conformance with this is monitored by the Ethics and Governance Council
(EGC). Thus the ethical focus is not only at the beginning of the research (at the
point of consent) but, by incorporating additional ethical and governance
mechanisms, occurs throughout the lifetime of the project or the research. The
EGC’s remit is:
‘‘acting as an independent guardian of the Ethics and Governance Framework
and advising the Board on its revision; monitoring and reporting publicly on
the conformity of the UK Biobank project within this Framework; and
advising more generally on the interests of participants and the general public
in relation to UK Biobank’’ ([19], p. 15).
Thus, ‘‘the Ethics and Governance Council will keep use of the resource under
review in order to advise on conformance with this Framework…to assure itself,
and others, that the resource is being used in the public interest’’ ([19], p. 13).
Therefore in this model broad consent is supplemented by the EGF and EGC, and
the processes which UK Biobank adopts, such as the access policy, have to be in
conformity with the EGF. Thus although ‘broad’ this consent is not empty—it is
bound overtime, thus respecting both the participants and their consent, and it is has
to be in public interest, thus going some way to respecting the needs of all, not only
those of the participants.
In addition to the rethinking of consent which biobanks have necessitated there
are a number of additional new ethical issues which biobanks raise; some of which
are connected to the consent issues. There is not enough time to do much more than
212 Health Care Anal (2011) 19:207–219
123
to list these and outline the ethical debate, but this in itself is sufficient to show why
biobanking challenges traditional ethical assumptions and has been given so much
attention in the field of ethics.
Confidentiality
A key feature of genetic information is that it is always potentially identifying, both
of the individual who donates the sample, and of those related to them (both now
and in the future). Thus, while identification can be discouraged—by various
process of anonymisation—it can never be fully guaranteed as identification is
potentially possible, for instance if samples are compared to a database. Thus, quite
simply confidentiality cannot be fully guaranteed—no matter how anonymised the
data is—as there is always a risk of identification. This risk grows as the number of
databases grows and thus the possibility of identification increases [21, 22]. Thus
while every effort can be made to annonymise date and to protect privacy in large-
scale biobanks which link to databases unintentional identification of individuals is
always possible. Given this full confidentiality should never be promised in
biobanking (or indeed in other areas of genetic research, although the linkages and
scale of biobanking make the risks more likely). This is of course in tension with the
traditions of medical ethics which, since the time of the Hippocratic Oath has
promised confidentiality.
Property and Profit
A second additional issue is about property and profit. The Ethics and Governance
Framework of UK Biobank states clearly (and three times) that participants have no
property in their samples. The view that participants have ‘no property’ in their
genetic samples has been based on a traditional understanding that body parts, once
detached, are res nullius, ‘no one’s thing’. Interestingly this traditional understand-
ing has more recently been challenged by advances in technology, particularly
where bodily materials are stored expressly for future usage of the donor in ways
that was once not viable [8, 26].
However, there are reasons for adhering to the ‘no property’ rule when it is
applied to samples in biobanks: Some reasons are practical as allowing property in
biobank samples would hinder the practice of research to the extent it would be
likely to become untenable; and some are ethical, they reject property in samples as
this might lead to the commodification of persons [5]. Yet while there are good
reasons for this view there are some dangers attached, particularly with regard to the
potential for commercial companies to make profits (and potentially very large
profits) from the research done on altruistically donated samples. Such profit making
is likely to feel to participants to be at odds with the public good rhetoric regarding
the aims of biobanks.
Some biobanks have responded by trying to show the compatibility between
public altruism and private profit. For instance, UK Biobank states that ‘‘The
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biotechnology and pharmaceutical industries can play an important role in realising
health benefits in a practical sense by developing and improving the use of
biomedical products. Commercial companies and other research endeavours that
stand to make a profit will, therefore, be allowed access to UK Biobank if their
proposal falls within the UK Biobank purpose and complies with the usual scientific
and ethics requirements’’ ([19], p. 18). In addition, biobanks (including UK
Biobank) are considering profit sharing methods or at least some mechanism for
ensuring that any profits gained does not turn into excessive profiteering. Others
make a distinction between different types of users; for instance, between
commercial and non-commercial users. Thus CARTaGENE operates a ‘‘differential
cost scheme for public, private and international researchers’’ ([7], p. 112).
The success of these various approaches in terms of satisfying participants and
the public and in terms of reducing and prevent excessive profiteering is yet to be
seen. However, getting this right is crucial for the survival of biobanking as
participants in biobanks have a tendency to regard their contribution as a duty to
other and part of being a good citizen. For instance in an Australian study Allen and
McNamara found that ‘‘consent to participate in biobank research is framed as the
moral act of a responsible citizen, which reinforces self identity and in the process
entrenches the perception of research as a public good’’ [1]. Thus this trust is
maintained by the ethics and governance procedures which accompany informed
consent, but also by ensuring that the public good is actually served. It is doubtful
that participants will view undue profiteering by private companies as serving the
public good and this may lead to mass withdrawal (the main threat to the success of
a biobanking project). How to address worries about unreasonable profiteering
remains an issue for biobanks and the jury is out on which is the best method and it
is to early to tell which approach will end up as standard.
Feedback
Another ethical issue which arises in research in general, but which is exacerbated
in biobanking, again because of the numbers involved, is that of whether or not to
feedback to participants ‘incidental findings’. While there is no standard definition
‘incidental findings’ they can broadly be described as ‘‘observations of potential
clinical significance unexpectedly discovered in healthy subjects, or in patients,
recruited to brain imaging research studies and unrelated to the purpose and
variables of the study’’ ([9] p. 783). The key issue is that they are ‘incidental’—
ascertaining information of clinical significance is not the aim of biobanks, rather
collecting material for later research is.
There are two points at which the feedback of incidental findings might be an
issue: when material is collected (if this is done specifically for the purposes of use
in the biobank) and at some future point in research. For instance UK Biobank
conducts its own collection of material which includes the taking of physical
samples, asking lifestyle questions, and then linking this information to health-
relevant records. UK Biobank’s policy to date has been to offer minimal feedback.
Participants are informed that the collection of material is not a clinical ‘health
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check’, but rather collection for the purposes of research, and thus they should not
expect feedback. However, even in this minimal feedback model it is judged that
‘‘even in this research context, there may be occasions when staff consider there to
be a professional or ethical obligation to draw attention to abnormal measurements
(such as elevated blood pressure) or incidental findings (such as possible
melanoma)’’ ([19], p. 7). Thus while rare there are instances where it will be
suggested to participants by UK biobank staff that they should contact their GP or
other relevant health professional. Incidental findings can also arise in future
research; and the likelihood that results are attained which have relevance for an
identifiable individual becomes more likely as links to additional databases increase,
so increasing the likelihood of unintentional identification. The rationale given for
the low level of feedback relates both the quality of the feedback, its usefulness and
its possible negative effects ([19], p. 7).
However, the failure to feedback has been criticised and the ethical justification
of limited feedback is being increasingly questioned. For instance, Johnston and
Kaye have argued that there is a duty to feedback to individual UK Biobank
participants for both legal and moral reasons. They argue that this is particularly the
case in the ‘‘rare situation …where the research reveals that an individual or his
family is at risk of a serious yet treatable condition’’ ([10], p. 267). The pressure to
feedback and the ethical questioning of the claim that feedback is only rarely
necessary at best is likely to increase as research progresses and as additional
enhancements are added to biobank resources. For instance, UK biobank is in the
process of attaining funding to carry out Magnetic Resonance Imaging (MRI) on a
sub-section of the original participants to enhance the biobank resource. It is
currently an open question whether the no (or very little) feedback policy will
continue if this is permitted. Unlike the initial visit the data which will be collected
from the MRI is not easily available elsewhere (as blood pressure results are, for
example), thus this scan might be the only point at which access to these results
might be possible. Also, as an MRI scan is generally regarded as a diagnostic tool
and used reveal any significant health problems, there is likely to be increasing
expectations on the part of the participants that they will be told if anything is wrong
(already a problem even at the base line assessment) [14]. Given these trends it is
likely that feedback will become an increasingly important ethical and policy debate
in the governance of biobanks.
Ensuring Participation, Representation and the Maintaining of Trust
As discussed, the biggest threat to biobanks is the mass withdrawal of participants—
if participants withdraw the biobank fails and if this happens early in the process
then the substantial set-up costs will be lost and there will be no gain at all—
therefore ensuring that participants and the wider public are appropriately engaged
with biobanks and that trust between these groups is maintained is crucial. However,
there are different models of possible engagement, from those where participants
(and in some biobanks the public) are very involved in the biobank—in terms of
directing future research and enhancements to the resource—to a model where there
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is no engagement as such but the biobank merely keeps participants informed.
These range from participant and/or consultative panels, patient and public
decision-making groups, citizens inquiries, participant and public shareholding in
the biobank, to participant and public seats on the biobank board. Just as with
property and profiteering there is as yet no one way which is viewed as best practice
and, as in so much of biobanking practice, what is good ethics and governance is yet
to be determined in this area.
Re-Contact
Like feedback, recontact is becoming an increasingly important issue. There is little
yet written on how recontact should be managed. But like issues of participation and
consent there is clearly a balance to be found between ensuring that participants are
as informed and included as they expect without over-burdening them. Just like
biobank samples, the ability to ‘re-contact’ should be seen as a ‘finite and
depleteable resource’. Thus, re-contact should be limited and mechanisms need to
be devised to ensure that this is still possible in the long-term. The likelihood is that
this will require biobanks to prioritise between research projects, however, exactly
how this will be done is another area in which there is currently no standard
procedures for biobanks to adopt.
This Issue
We have said that informed consent, problems it faces in biobanking and the need
for alternative models are a key source of issues in biobanking ethics. Unsurpris-
ingly then, several of the papers in this issue concern or touch on the questions of
informed consent. In their analysis of the ‘New Belgian Law on Biobanks’ Sigrid
Sterckx and Kristof Van Assche note some of the legal and ethical implications of
this law regarding consent, for example that it allows for ‘presumed consent’ to
research in the case of ‘residual materials’. Interestingly, and worryingly for Sterckx
and Van Assche, such material is deemed ‘residual’ if it was extracted for
diagnostic purposes, but unless the patient explicitly requests otherwise their
consent to its use in research is, apparently, not merely ‘tacitly assumed’ but
‘presumed’.Tacit consent to certain instances of research is one thing when a donor
has agreed that their material at least may be used in some kind of research, but it is
quite another in cases where no such agreement obtains.
In ‘Respect for Autonomy: its Demands and Limits in Biobanking’, Iain Law
takes up the question of autonomy, more specifically the notion of autonomy
employed in discussions of informed consent and the level of information required
to respect such autonomy. If we are to make respect for donor autonomy a
cornerstone of biobanking ethics, then we need to be clear about what it is we mean
by autonomy and what a requirement to respect it does and does not entail. The
constraints of autonomy in the context of biobank research, on Law’s view, entail
only that a consenting person is not deceived, so will not entail a requirement
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actively to supply full information at every stage of a biobank’s activity involving
participants, for example. An interesting implication of his paper is that talk about
autonomy is often loose, and there is no reason to think that it is any more careful in
bioethics. Hence the issue of informed consent in relation to biobank research is one
where it should be more precise.
Søren Holm looks specifically at the question of participant withdrawal from
biobanks. He begins his paper ‘Withdrawing from Research—A Rethink in the
Context of Research Riobanks’ by observing that whilst it would be impossible to
account for everything that has been written on the conditions for participation in
research, it might prove similarly difficult to find literature on the conditions for
withdrawal. Having granted that there are some good historical reasons and
principles to defend the ‘established view’ of the right to withdrawal, on which that
right is: absolute; unconditional; immediate; and complete, he argues that there may
be cases in which components of this right should be relaxed, so on this view the
right to withdraw is not inalienable, nor is it necessarily unconditional.
Other papers in this issue start or overlap with questions of consent, whilst also
considering some of the other problems outlined above (1–7). Sean Cordell
motivates his account of ‘The biobank as an Ethical Subject’ by taking the debate
over consent as a crystallizing example of the broad ethical and socio-political terms
in which biobanking issues are conducted, where for example individual rights are
balanced with public health and future benefits to entire populations. What is
missing from this debate, he then claims, is a more determinate understanding of the
biobanking institution as an entity with certain internal standards of conduct derived
from ‘what it is there for’, from its being ‘fit for purpose’. When that purpose is
construed as essentially connected to certain human goods of health and research in
ways specific to biobanking, it can be understood as something which places certain
ethical limits on its activities.
Continuing with how a biobank is understood or perceived, an important question
is that of how public participants view their own relationships with a biobank. This
question relates most conspicuously to the topics of feedback (5), trust and
continuing participation (6) and the extent to which participants should, or might
expect to be re-contacted (7). Mairi Levitt focuses on these topics in ‘Relating to
Participants: How Close do Biobanks and Donors Really Want to Be?’ She looks at
the ways in which biobanks appeal to donors and present the co-operative enterprise
of the biobank and its projects, and at how participants themselves respond and
envisage this relationship. An interesting conclusion is that for a biobank getting the
‘right’ relationship could mean more than only establishing the one that, for
example, ensures continued participation. This is because different kinds of
relationship bring with them different expectations and obligations. So whilst public
engagement is crucial, so is considering the terms of that engagement—for example
are we ‘acquaintances’ or more like ‘friends’?—and being clear about what kind of
feedback and degree of confidentiality is to be expected.
All of the ethical issues raised here should of course be those considered in
constructing and implementing actual ethical guidelines and regulations. An
important and overarching issue in this respect is about who does the constructing
and implementing and on what basis. This is tackled by Jean McHale in
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Accountability, Governance and Biobanks: The Ethics and Governance Committee
as Guardian or as Toothless Tiger’. In the context of the UK, McHale explores
whether it is correct to regard Ethics Committees as such ‘‘toothless tigers’’, and
considers alternative structures which may provide a more appropriate regulatory
paradigm for the future. More specifically the question of whether the ethics
committee serves as ‘legitimator’ of research or as a means of ensuring
accountability (or both). Acknowledging good reasons of objectivity and indepen-
dent perspectives for ethics committees to exist, McHale expresses the worry that
the ethics committee is nevertheless all too ‘toothless’. Hence her article provides a
critical view of the legal framework within which ethical issues and recommen-
dations are discussed, and of how this framework might be improved.
As can be seen just from this overview, the topic of biobanking presents
significant and distinct ethical challenges. As stated in the introduction, the aim of
this special issue is to advance the important and developing debates about these
challenges in a number of ways. In addition it is also hoped that the wide and inter-
disciplinary nature of this collection will underline and reflect both the interest in,
and the importance of, biobanking, a topic that potentially impinges on so many
areas of human life.
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